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Introduction: Apical ballooning syndrome or Takotsubo cardiomyopathy 
is an acute syndrome characterized by cardiac failure from disturbances in the 
contractility of the left ventricle. It is presumably caused by sympathetic over 
stimulation.
Case presentation: We describe the case of apical ballooning syndrome in 
a 17-year-old male after receiving accidently 2 mg of norepinephrine. 
The patient was admitted to the reanimation unit for severe sepsis with dis-
seminated intravascular coagulation and acute renal failure. The LVEF was 
controlled at the admission and was normal. After accidental flash of norepi-
nephrine, the patient developed pulmonary edema. The electrocardiogram 
showed depression of ST segment in apical leads. The transthoracic echocar-
diogram revealed a large akinesia of the apex which seemed ballooned. The 
left ejection fraction was about 45%.
During 48 hours, the patient needed vasoactive drug infusions of dobuta-
mine and non-invasive ventilation. There was pseudonormalization of ventric-
ular repolarization on ECG. The evolution was good after 2 days with 
imporvement of LVFE at chocardiogram. A cardiac MRI performed 7 days 
later found a normal left ventricular function withaout any late enhancement.
Conclusion: This case illustrates that infection is a condition that could 
make the myocardium vulnerable to cathecolamine. 
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Introduction: Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease with a large clinical polymorphism. Many factors: genetic, endocrine, 
immunological and environment contribute to disease onset. SLE is character-
ized by the involvement of multiple viscera, particularly the kidney, the heart 
and the skin. Cardiac manifestations are relatively common and can involve 
life-threatening.
Materials and methods: This is a retrospective descriptive study out of 
ten years, on the records of patients admitted in our department of internal 
medicine for LES (final diagnosis according to the criteria of the American 
Rheumatology Association: ACR). We studied the case with cardiac events.
Results: In a series of 80 cases of SLE patients, cardiac involvement was 
retained in 70% of patients. It was dominated by pericarditis in 52% of cases 
and it was symptomatic in 30% of them. Ultrasound noted endocarditis in 
44% of cases with lesions of the mitral valve in 74% of cases. Myocarditis 
with left ventricular failure was observed in six patients. These events had 
occurred at the beginning of the disease in 60% of patients. Indeed, patients 
had dyspnea in 30% of cases, chest pain in 25% of cases. At ECG, a micro-
voltage was noted in 40% of cases (pericarditis). Echocardiography has 
contributed to the diagnosis of pericarditis, myocarditis and endocarditis. The 
treatment was the strengthening of corticosteroids.
Conclusion: Cardiac manifestations of SLE are severe and asymptomatic 
in most cases. Their research must be systematic in order to treat earlier. 
Ultrasound appears to be the first-line examination in the detection of cardiac 
involvement in SLE. The prognosis remains severe coronary insufficiency and 
rhythm disorders.
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Background: Cardiac involvement in ankylosing spondylitis is common. 
We have tried through this study to analyze the cardiovascular events among 
50 patients with ankylosing spondylitis.
Methods: A retrospective study including 50 patients with ankylosing spondy-
litis. All patients underwent a complete physical examination with a heart and lung 
auscultation and an electro-cardiogram (ECG). Transthoracic ultrasound was per-
formed whenever there was an abnormal physical examination and/ or ECG.
Results: The study included 47 men and 3 women, the sex ratio is 15,6. 
The average age of onset was 26±7 years. The mode of onset is axial in 95% 
of cases (low back pain and/or buttock). The extra-articular manifestations are 
present in 54% of cases. Cardiac involvement is present in 9 cases (18% of 
cases). The reason for consultation is dyspnea in 2 patients. In other cases, 
cardiac involvement was discovered incidentally. Aortic regurgitation was 
noted in 4 patients. Mitral insufficiency was found in 3 cases. Two patients 
have predominantly septal hypertrophic cardiomyopathy and one patient pre-
sented an array of pulmonary insufficiency. The average time of onset of car-
diac involvement was 8± 5 years. All patients were put under special medical 
treatment of their heart, with good clinical outcome.
Conclusion: Cardiac involvement in ankylosing spondyllitis is seen more 
frequently in men, especially in the old cases. A close relationship between 
time to onset of aortic insufficiency and duration of disease progression was 
found. It would be responsible for one third of deaths of patients. It was sig-
nificantly more frequent in HLA B27 positive patients (especially complete 
atrioventricular block and aortic insufficiency).
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Background: Doxorubicin (DOX), an anticancer anthracycline, is known 
to induce serious cardiotoxicity, which is believed to be mediated by oxidative 
stress and complex interactions with iron. However, the relations between iron 
metabolism and DOX-induced cardiotoxicity remain a matter of controversy.
Methods: Firstly, we used an in vivo murine model of iron overloading (IO) 
where male C57BL/6 mice received during 3 weeks (D0-D20) a daily dextran-
iron injection (15 mg/kg/day.) and then (D21) a single dose of 6 mg/kg DOX. 
We evaluated cardiac function with echocardiography, myocardial gene’s 
expression, nitro-oxidative stress levels and iron status. Secondly, the anti-pro-
liferative activity of DOX, in combination with dextran-iron, was evaluated in 
vitro in cultures of cancerous cells (EMT-6) or cardiomyocytes (H9c2).
Results: At D30, there was a significant decrease in left-ventricular ejec-
tion fraction (LVEF) in all groups of DOX-treated mice. In IO mice treated by 
DOX, the LVEF fall was not majored and there was no increase in atrial natri-
uretic peptide mRNA cardiac gene-expression. IO alone resulted in cardiac 
hypertrophy and up-regulation of b-myosin heavy-chain expression. In myo-
cardial tissue, electron spin resonance spectroscopy revealed an increase in 
nitro-oxidative stress in IO groups. While 1 μM of DOX induced a significant 
reduction of EMT-6 or H9c2 cells proliferation, dextran-iron (125-1000 μg/mL)
alone did not modify cell viability and did not impair DOX cytotoxicity.
Conclusions: IO did not result in a significant increase in DOX cardiotox-
icity neither in mice, nor in cardiomyocytes, and did not impair DOX capacity 
to inhibit cancerous cells proliferation.
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